Skip to main content
Premium Trial:

Request an Annual Quote

Caprotec Raises $5M in Series B Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German protein reagents and sample prep technology firm Caprotec Bioanalytics said yesterday that it has closed on a €4 million ($5 million) Series B financing round.

Proceeds will be used to further develop its Capture Compound Mass Spectrometry technology for analyzing complex protein mixtures, the firm said in a statement. Specifically, Caprotec will continue development of its caproKits for the identification of functionally selected protein classes, as well as its ImproMed application for profiling drug interactions.

Participants in the financing included existing investors Creathor Venture, IBB Beteiligungsgesellshaft, ERP Startfonds, and private investors, the Berlin-based company said.

Caprotec's technology, called CCMS, is based on tri-functional molecules called capture compounds, and can be used to define and confirm drug targets and to discover off-target proteins that cause side effects.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.